Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

This study is testing SMART101, a specialized immune cell therapy, in patients with blood cancers (leukemia or pre-leukemia) who are receiving a bone marrow transplant from a half-matched family donor. The goal is to reduce the risk of relapse and improve immune recovery after transplant. **You may be eligible if...** - You are 18 or older - You have AML (acute myeloid leukemia), ALL (acute lymphoblastic leukemia), or MDS (myelodysplastic syndrome) - You are eligible for a bone marrow transplant from a half-matched (haploidentical) family donor - You have adequate heart, lung, liver, and kidney function - Your Karnofsky performance score is 70 or higher (able to carry out normal activity with some effort) **You may NOT be eligible if...** - You have other serious medical conditions that would prevent transplant - You do not have a suitable haploidentical donor Talk to your doctor to see if this trial is right for you.